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ALLOGENEIC STEM CELL TRANSPLANTATION (allo-SCT) FROM A HLA
IDENTICAL SIBLING FOR CR1 AML PTS AGED ABOVE 55 YEARS OLD
AFTER A REDUCED INTENSITY CONDITIONING: A RETROSPECTIVE
STUDY FROM THE SOCIE´TE´ FRANC¸AISE DE GREFFE DE MOELLE ET DE
THE´RAPIE CELLULAIRE (SFGM-TC)
Blaise, D.1, Chir, Z.2, Attal, M.3, Bourhis, J.H.4, Sotto, J.J.5,
Boiron, J.M.6, Milpied, N.7, Cahn, J.Y.8, Rio, B.9, Lioure, B.10,
Berthou, C.11, Buzin, A.12, Michallet, M.13 1. Institut Paoli-Calmettes,
Marseille, France, Metropolitan; 2. SFGM-TC, Paris, France, Metro-
politan; 3. CHU de Purpan, Toulouse, France, Metropolitan; 4. Institut
Gustave Roussy, Villejuif, France, Metropolitan; 5. Hopital Albert
Michalon, Grenoble, France, Metropolitan; 6. EFS Aquitaine- Limou-
sin, Bordeaux, France, Metropolitan; 7. Groupe Hospitalier Haut
Leveque, Bordeaux, France, Metropolitan; 8. Hopital Jean Minjoz,
Besancon, France, Metropolitan; 9. Hotel Dieu, Paris, France, Metro-
politan; 10. Hopital de Hautepierre, Strasbourg, France, Metropolitan;
11. CHU Augustin Morvan, Brest, France, Metropolitan; 12. Hopital
Necker, Paris, France, Metropolitan; 13. Hopital Edouard Herriot,
Lyon, France.
AML incidence increases with age. Allo-SCT offers the best leuke-
mic control but is associated with high non-relapse mortality (NRM).
Recent advances using non-myeloablative strategies have established
the feasibility of allo-SCT in elderly patients (pts). However, in the
context of AML, a much too important reduction of preparative
regimen might be associated with a loss of leukemic control offsetting
the impact of toxicity reduction in elderly.To get some clues on this
subject, we retrospectively analyzed CR1 AML pts reported to the
SFGM-TC, aged above 55 and transplanted from a HLA identical
sibling prior to 01/01/05. Sixgty-two pts prepared with a non-myeloa-
blative conditioning (NMAC) (Fludarabine [75mg/m2]TBI [2Gy])
(n  14) or a reduced intensity conditioning (RIC) (busulfan [4 to 8
mg/m2]  ﬂudarabine [150 to 180 mg/m2]  thymoglobulin [2.5 to
12.5 mg/m2]) (n  48). GVHD prophylaxis used CSA  MMF for
NMAC, CSA / MMF for RIC. With few exceptions, all pts in a
given center were treated identically. Major characteristics: age 58
(55–67), M/F  27/35, time diagnosis-SCT: 171 days (101–467),
BMT/PBSCT: 7/55. Pts have been considered for allo-SCT for
presenting poor prognosis factors: no favorable cytogenetics (100%),
secondary leukemia (15%), 2 chemotherapy course to achieve CR1
(24%), or M0, M6, or M7 FAB (20%). All pts engrafted. AGVHD
occurred in 16 pts (grade 1: 6; grade 2: 6; grade 3–4: 4), and cGVHD
in 18 pts (limited: 8; extensive: 10) with no difference in the 2 groups.
The cumulative incidences of grade 2–4 aGVHD and cGVHD were
16% (95%CI: 7–25) and 29% (95%CI: 18–40), respectively. Fifteen
pts relapsed and 8 died from NRM. Relapse and NRM cumulative
incidences were 24% (95%CI: 13–35) and 13% (95% CI: 5–21),
respectively. Forty-nine pts were evaluable for cGVHD: of the 18
expressing cGVHDnone have relapsed compared to 12 of the 31 who
did not present cGVHD (39%, 95%CI: 22–56) ( P .007). Two year
KM survival and DFS probabilities are 63% (47–76) and 56% (42–
69). In a landmark analysis investigating pts alive on day 100, 2 year
DFS are 94% and 38%, respectively, with or without cGVHD (P 
.001) and 2 year KM OS are 94% and 45%, respectively, (P  .01).
We conclude that such a strategy in elderly can afford a high relapse
control with low NRM conducting to high survival probability at 2
years. Results are achieved through the allogeneic effect as expressed
by cGVHD inviting to a careful immunomodulation in the early post
transplant period to further improve results.
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EARLY PREDICTION OF EXTRAMEDULLARY RELAPSE OF LEUKEMIA
FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION USING THE
WT1 TRANSCRIPT ASSAY
Yoshihara, S.1, Tamaki, H.1, Ikegame, K.1, Kawakami, M.1,
Fujioka, T.1, Taniguchi, Y.1, Kaida, K.1, Hasei, H.1, Inoue, T.1,
Murakami, M.1, Masuda, T.1, Kim, E.H.1, Soma, T.1, Ogawa, H.1,2 1.
Department of Molecular Medicine, Osaka University Graduate School
of Medicine, Suita, Osaka, Japan; 2. Department of Internal Medicine,
Division of Hematology, Hyogo College of Medicine, Nishinomiya,
Hyogo, Japan.
Extramedullary (EM) relapse of leukemia after allogeneic stem
cell transplantation (allo-SCT) is increasingly reported. However,
its diagnosis is often delayed due to the diversity of the involved
sites and the lack of monitoring methods. In the present study, we
investigated the role of monitoring of the WT1 gene expression in
the early diagnosis with EM relapse. Methods: Between January
1998 and December 2003, 97 patients with AML (n  42), ALL
(n  22), CML (n  23), or MDS (n  10) underwent allo-SCT
at Osaka University Hospital. We retrospectively monitored the
WT1 gene expression level in the patients who had a bone marrow
(BM) or EM relapse after allo-SCT. Quantiﬁcation of the WT1
gene expression in BM and peripheral blood (PB) samples was
serially performed using real-time PCR. Results: Twenty-two out
of 97 patients who underwent allogeneic SCT had a relapse. Three
patterns of leukemia relapse were observed; BM relapse (17 pa-
tients), isolated EMR (4 patients), and EMR with BM relapse (1
patient). Among them, in 12 patients with BM relapse and 3
patients with isolated EMR, the WT1 expression levels in the BM
and PB could be concurrently monitored after transplantation. In
all the patients having a BM relapse, the WT1 expression levels in
the BM were greater than 1.0  102, and all these values were
higher than those in the PB. In contrast, in all 3 patients having an
EMR, the WT1 expression levels in the PB were abnormally high
(	1.0  103), and were higher than those in the BM even 11 to
46 days before the diagnosis. The BM/PB ratio of the WT1 gene
expression at the time of diagnosis of relapse was signiﬁcantly
lower in the patients with isolated EMR when compared with the
patients with BM relapse (P  .01). Conclusions: We demon-
strated, for the ﬁrst time, that an abnormally high WT1 expression
level in PB, which was greater than that in BM, was observed
exclusively in the patients with isolated EM relapse. Thus, a con-
current monitoring of MRD in BM and PB must be useful for early
diagnosis of EM relapse.
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A PILOT STUDY EVALUATING THE SAFETY AND EFFICACY OF IMATINIB
GIVEN EARLY AFTER TRANSPLANT FOR HIGH-RISK PHILADELPHIA
CHROMOSOME-POSITIVE LEUKEMIAS
Carpenter, P.A.1, Snyder, D.S.2, Flowers, M.E.1, Sanders, J.E.1,
Martin, P.J.1, Radich, J.P.1 1. Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA; 2. City of Hope Cancer Center, Duarte, CA.
Patients with Ph acute lymphoblastic leukemia (ALL) or
chronic myelogenous leukemia (CML) in stages other than ﬁrst
chronic phase (CP1) frequently have recurrent malignancy after
allogeneic hematopoietic cell transplant (HCT). Hypothesis: We
postulated that imatinib might be most effective for preventing
hematological relapse after myeloablative HCT if given immedi-
ately after engraftment to patients without detectable leukemia, or
with leukemia that can be detected only at the molecular level.
Study Design: A pilot study to evaluate the safety and preliminary
efﬁcacy of imatinib given early after engraftment until post-trans-
plant day 365 (D 365) nears complete accrual. Study participants
became eligible to start imatinib if the residual marrow leukemia
burden at the time of initial engraftment (ANC 	500 on 2 con-
secutive days) did not exceed 	1/20 Ph metaphases, 	1% aber-
rant antigen expression on blasts by multidimensional ﬂow, or
presence of bcr/abl in 	5% interphase nuclei by FISH. The
primary endpoint of safety was deﬁned by ability to tolerate ima-
tinib for 6 days/week until D  90. Patient Characteristics and
Results: (see Table below). All patients tolerated imatinib at the
intended dose intensity within the ﬁrst 90 days after HCT. Tox-
icities (NCI CTC v3.0) possibly attributed to imatinib included
grade 1–2 nausea (n 3), grade 1 edema (n 3), grade 1–2 anemia
(n 2), and grade 3 neutropenia (n 2). Per protocol, one patient
with neutropenia received 2 doses of G-CSF at D  75 and
continued imatinib without neutropenia. The second patient was
not given G-CSF and imatinib was held for 2 weeks from D  160
until the ANC was 	2000. All patients are alive at a median of 250
days after HCT (range, 27–627), and 17/18 patients have no
detectable bcr/abl transcripts in the blood or marrow. Seven pa-
tients ( ALL, 3 CML) have completed imatinib therapy and survive
at a median of 515 days after HCT (range, 416–627 days) and
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none has detectable bcr/abl transcripts in blood or marrow. One
patient (CML-CP3) with cytogenetic relapse at D  118 had a
fourth remission after withdrawal of immunosuppression and con-
tinued imatinib but developed hematological relapse at D  429.
Conclusions: We conclude that imatinib therapy can be safely
prescribed early after myeloablative allogeneic HCT at a dose-
intensity comparable to that used in general oncology. Preliminary
efﬁcacy data are encouraging and worthy of further study (Table1).






Disease phase, N CR1 10, CR2 2
AP 2, CP2 2, CP3
2
Patients with MRD1 present, N 9 6
Median age, years (range) 36 (5–49) 45 (36–62)
Related donor, unrelated
donor, N 5, 7 2, 4
Peripheral blood, marrow,
cord blood, N 8, 3, 1 4, 1, 0
Posttransplant outcomes
Imatinib therapy start day,
median (range) 28 (24–39) 29 (25–36)
Imatinib therapy, days of,
median (range) 183 (3–381) 243 (89–353)
Average daily imatinib doses,
milligrams
<Day 90, median (range) 400 (2122–400) 400 (novariance)
>Day 90, median (range) 400 (2502–550) 400 (novariance)
Survival, days, median (range) 214 (27–600) 511 (130–627)
Molecular
remission/completed
therapy, N/N 4/4 3/4
Molecular remission/continue
Imatinib, N/N 8/8 2/2
1MRD  minimal residual leukemia by cytogenetic and/or molec-
ular methods.
2Two children did not receive 400 mg per day but received close to
340 mg/m2/day.
247
DIFFERENCES IN THE PHENOTYPE AND IN VIVO ANTI-TUMOR ACTIV-
ITY OF WT1 SPECIFIC AND EBV-SPECIFIC T-CELLS GENERATED IN
VITRO FOR ADOPTIVE IMMUNOTHERAPY
Doubrovina, E.1, Dupont, J.1, Kanaeva, E.1, Doubrovin, M.1,
O’Reilly, R.1 Memorial Sloan-Kettering Cancer Center, New York, NY.
Our studies in SCIDmouse/human tumor xenograft models have
demonstrated that T cells sensitized with autologous EBV BLCL
in vitro will, following intravenous transfer into mice bearing
tumors varying in HLA type and expression of EBV antigens,
selectively accumulate in EBV tumors co-expressing the T cell’s
HLA restricting allele, and will proliferate and persist in these
tumors through there complete regression. In contrast while T
cells sensitized against WT1 peptides presented by peptide-loaded
autologous DCs or EBV BLCL in vitro also exhibit HLA-re-
stricted accumulation in WT1 tumor xenografts and induce
signiﬁcant inhibition of tumor growth, they persist only for periods
of 8 days following adoptive transfer. By day 15, the T cells were
no longer detectable in the tumors, following which the regrowth
of WT1 expressing tumors was again observed. Accordingly, we
compared T cells sensitized in vitro with autologous EBV BLCL
alone or with EBV BLCL loaded either with the pool of overlap-
ping 15-mers spanning over WT1 sequence or transduced to
express WT1. Antigen-speciﬁc T cells were then characterized as
to their speciﬁcity and HLA restriction. Antigen-reactive T cells
were then isolated on the basis of IFN production in response to
secondary restimulation with APCs bearing targeted peptides and
the appropriate restricting HLA alleles and evaluated for their
phenotype and tumor-speciﬁc activity. Both CD4 and CD8
EBV-speciﬁc T cells exhibited HLA-restricted lysis of EBV
tumor cells while the CD8 WT1 speciﬁc T cells consistently
lizedWT1 tumors bearing HLA restricting HLA class I allele. The
CD4 T cells were not cytotoxic. The WT1-speciﬁc and EBV-
speciﬁc CD4 T cells did not differ in phenotype. However, while
CD8 T cells speciﬁc for EBV expressed an effector memory
phenotype (CD3 CD8 CCR7 CD45RA CD45RO
CD62L CD25), the WT1 speciﬁc CD8 T cells were predom-
inantly of a central memory type (CD3 CD8 CCR7
CD45RA CD45RO CD62L CD25). These studies suggest
that T cells generated against WT1 in vitro may be relatively
deﬁcient in effector memory T cells required to induce complete
tumor regression in vivo.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR MALIG-
NANCIES USING UMBILICAL CORD BLOOD UNITS (UCB) THAT WERE
NOT RED BLOOD CELL DEPLETED
Chow, R.1, Nademanee, A.2, Rosenthal, J.2, Karanes, C.2,
Graham, M.3, Tan, P.4, Jaing, T.-H.5, Gjertson, D.6, Petz, L.1 1.
StemCyte International Cord Blood Center, Arcadia, CA; 2. City of
Hope National Medical Center, Duarte, CA; 3. University of Arizona
Medical Center, Tuscon, AZ; 4. Mount Elizabeth Hospital, Singapore,
Singapore; 5. Chung Gung Memorial Hospital, Linko, Taiwan; 6.
UCLA Medical Center, Los Angeles, CA.
Cell dosage is a limiting factor for UCB HSCT, especially for adult
patients. Most UCB banks practice red cell depletion (RCD) tech-
niques to save storage space, which incur signiﬁcant nucleated cell loss
after processing. One method of minimizing cell loss and still reduce
volume after processing is to deplete plasma (PD), but not the red
blood cells. Not washing UCB after thawing also minimizes cell loss.
A large, racially diverse PD UCB inventory of 18,000 units is now
available on stem cell registries. A retrospective analysis was per-
formed on 70 patients with malignancies without prior HSCT who
were transplanted during remission with PD UCB. There were 28
ALL, 16 AML, 8 CML, 7MDS/RA/RAEB, 3 JMML, and 8 others.
Of the ALL/AML/CML cases with available information, there were
19 1CR/CP, 10 2CR, and 9 3CR/CP. The median age of patients was
5.8 years old (range 0.5–54); median weight 23 kg (range 5–84); male
63%. Transplant characteristics indicated a median # HLA ABDR
matches of 5.0 (11-6/6; 23-5/6; 27-4/6; 8-/6; 1-/6;) median pre-freeze
TNC dose 6.4 107/kg; median post-thaw TNC dose as reported by
TC 5.3  107/kg; median pre-freeze CD34 dose 2.5  105/kg;
transplants outside of U.S. 24%; double unit transplant 14%; non-
myeloablative 7%. Forty-seven percent of the transplanted UCBwere
washed post-thaw (W), 33% were infused without post-thaw wash
(NW), with 20% of the units without available post-thaw data. Me-
dian time to engraftment for ANC 500 (n  66), platelet 20K (n 
52), and 50K (n 50) were 24 days (range 7–49 days), 53 days (range
15–94 days), and 63 days (range 37–132 days), respectively. Median
time to engraftment for W versus NW were 28 versus 23 days for
ANC500, and 55 versus 49 days for platelet 20K, respectively. The
unadjusted cumulative incidence (C.I.) of ANC500 and platelet 20K
and 50K engraftments are 93  3%, 76  6%, and 75  6%,
respectively. The incidence of reported grade II-IV and III-IV acute
GVHD were 37% and 20%, respectively. Twelve percent developed
limited chronic GVHD and 15% developed extensive chronic
GVHD. With a median follow-up of 282 days (range 50–1263 days),
the Kaplan-Meier estimates of 1-year TRM, OS and relapse-free
survival were 20  6%, 67  6%, and 59  7%, respectively. These
results demonstrate that HSCT using unrelated PD UCB can be
performed safely and effectively in patients with malignancies, and
post-thaw wash may not be necessary.
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OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION AFTER ADDING HIGH-DOSE CYTARABINE TO THE CONVEN-
TIONAL Cy/TBI CONDITIONING REGIMEN FOR THE TREATMENT OF
PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC
LEUKEMIA
Yoo, K.H.1, Kook, H.2, Sung, K.W.1, Jung, H.-L.1, Koo, H.H.1,
Baek, H.J.2, Hwang, T.J.2 1. Department of Pediatrics, Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul,
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